Cetuximab
Code | Size | Price |
---|
TAR-T9905-1mg | 1mg | £229.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9905-2mg | 2mg | £303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9905-5mg | 5mg | £458.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9905-10mg | 10mg | £630.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9905-25mg | 25mg | £962.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Cetuximab (anti-EGFR) a novel molecular-targeted agentis an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation.
CAS:
205923-56-4
Formula:
C107H179N35O36S7
Molecular Weight:
152kd
Pathway:
JAK/STAT signaling; Tyrosine Kinase/Adaptors; Angiogenesis
Purity:
0.98
SMILES:
0
Target:
EGFR
References
H, Gustafsso, A, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model[J]. Cell Biochemistry & Biophysics, 2017.
Komatsu M, Nakamura K, Takeda T, et al. Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling. Oncogene. 2022: 1-14.
Huang S M , Bock J M , Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res, 1999, 59(8):1935-1940.